Proteostasis Therapeutics
Merged with Yumanity Therapeutics in 2020
Developing therapies targeting protein misfolding diseases.
F-Prime Team
Sector
Life SciencesCategory
TherapeuticsStatus
AcquiredLocation
Cambridge, MAInitial Investment
2008
Developing therapies targeting protein misfolding diseases.
Proteostasis Therapeutics (NASDAQ: PTI) is a drug discovery company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Proteostasis Therapeutics merged with Yumanity Therapeutics in 2020.